Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Pharmaceutical > Generic Drugs > Generic and Biogeneric Drugs for 15 Major Therapeutic Categories: U.S./ E.U./ Japan/ ROW Market Trends and Directions 2008-2013
Category
Pharmaceutical (5003)
Bone Disease Treatment (46)
Cancer (894)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (407)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (562)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

Generic and Biogeneric Drugs for 15 Major Therapeutic Categories: U.S./ E.U./ Japan/ ROW Market Trends and Directions 2008-2013

Published by Fuji-Keizai U.S.A., Inc.
Published January, 2010 Product code 106713
Content info 269 PAGES
Price
US $ 1795 Hard Copy: English Version
US $ 1795 Hard Copy: Japanese Version
US $ 2495 PDF by E-mail (Department License): English Version
US $ 2495 PDF by E-mail (Department License): Japanese Version
US $ 3995 PDF by E-mail (Corporate License): English Version
US $ 3995 PDF by E-mail (Corporate License): Japanese Version


Generic and Biogeneric Drugs for 15 Major Therapeutic Categories: U.S./ E.U./ Japan/ ROW Market Trends and Directions 2008-2013 published by Fuji-Keizai U.S.A., Inc. in January, 2010. This report consists of 269 PAGES and the price starts from US $ 1795.

Introduction

Abstract

This report reviews, analyzes and sizes the generic and biogeneric drug markets, particularly focusing on new biogeneric medicines.

This report assesses the generic prescription market and maps the competitive landscape. The market forecast section sizes the market and discusses the five-year revenue projection to 2013. The market is segmented by key therapeutic applications, into major world regions of U.S., EU, Japan and rest of world (ROW), with drugs identified by active ingredient and brand name (in parentheses).

It covers the major therapeutic indications for generic medicines:

  • Allergy Drugs
  • CNS and Psychotherapeutic Drugs
  • Analgesics, NSAIDs and Antirheumatic Drugs
  • Cholesterol Reducers
  • Anesthesia Drugs
  • Diabetes Drugs
  • Anti-Convulsants
  • Gastrointestinal Drugs
  • Anti-Infectives
  • Hormonal Drugs
  • Cancer Drugs
  • Osteoporosis Drugs
  • Cardiovascular Drugs
  • Sleeping Agents & Sedatives

Primary information for this report was gathered from numerous sources including in-person interviews and discussions, telephone interviews, and surveys, attendance at business presentations at healthcare technical and financial conferences as well as through secondary research.

This market research study is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and the like. More than 200 detailed tables and figures provide key data about items such as revenues and market size, market share, segments and the like. This report includes 37 company profiles that provide the reader a snapshot of the companies' focus or activities. Internet links help readers access companies' own web sites for further review.

Targeted Company: Actavis Group, Analiza Inc., Apotex, Aurobindo Pharma, Bedford Laboratories, Biocon, BioGeneriX Ag, Biopartners GmbH, Cangene Corporation, Dr. Reddy' s Laboratories, Dragon Pharmaceuticals Inc., Hospira, Inc., Lupin Pharmaceuticals, Microbix Biosystems, Momenta Pharmaceuticals, Mylan Inc., Nichi-Iko Pharmaceutical, Nipro Pharma Corp., Orchid Chemicals and Pharmaceuticals Ltd., Par Pharmaceuticals, Perrigo, Pfizer, Phage Biotechnology Corp., Ranbaxy Laboratories, Ratiopharm, Reliance GeneMedix plc, Roxane Laboratories, Sandoz, Sawai Pharmaceutical Co., Stada Arzneimittel Ag, Taisho Pharmaceutical Industries, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Towa Pharmaceutical, URL Pharma, Watson Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc.

Report Statistics

  • Published: January 12, 2010
  • Total Page: 269 pages

Table of Contents

Executive Summary

1. Global Market: Generic and Biogeneric Drugs

  • 1.1 The Global Generic and Biogeneric Drug Landscape
    • 1.1.1 Global Healthcare Spending
    • 1.1.2 Global Prescription Volume for Generic and Biogeneric Drugs
    • 1.1.3 Global Sales of Generic and Biogeneric Drugs
      • 1.1.3.1 Global Sales of Generic and Biogeneric Drugs by Company
        • Table 1.1: Sales by Company, 2008
        • Figure 1.1: Market Positions (Share) by Company, 2008
      • 1.1.3.2 Global Sales of Generic and Biogeneric Drugs by Category
        • 1.1.3.2.1 Allergy Drugs
          • Table 1.2: Sales by Indication/Drug Name 2008
          • Figure 1.2: Market Positions (Share) by Drug Name, 2008
          • Table 1.3: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.3: Sales by Brand, 2008 - 2013
        • 1.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
          • Table 1.4: Sales by Indication/Drug Name, 2008
          • Figure 1.4: Market Positions (Share) by Drug Name, 2008
          • Table 1.5: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.5: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.3 Anesthetics
          • Table 1.6: Sales by Indication/Drug Name, 2008
          • Figure 1.6: Market Positions (Share) by Drug Name, 2008
          • Table 1.7: Sales of by Brand in $MM, 2008 - 2013
          • Figure 1.7: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.4 Anti-Convulsants
          • Table 1.8: Sales by Indication/Drug Name, 2008
          • Figure 1.8: Market Positions (Share) by Drug Name, 2008
          • Table 1.9: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.9: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.5 Anti-Infectives
          • Table 1.10: Sales by Indication/Drug Name, 2008
          • Figure 1.10: Market Positions (Share) by Drug Name, 2008
          • Table 1.11: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.11: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.6 Cancer Drugs
          • Table 1.12: Sales by Indication/Drug Name, 2008
          • Figure 1.12: Market Positions (Share) by Drug Name, 2008
          • Table 1.13: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.13: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.7 Cardiovascular Drugs
          • Table 1.14: Sales of by Type/Drug Name, 2008
          • Figure 1.14: Market Positions (Share) by Drug Name, 2008
          • Table 1.15: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.15: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.8 CNS and Psychotherapeutic Drugs
          • Table 1.16: Sales by Type/Drug Name, 2008
          • Figure 1.16: Market Positions (Share) by Drug Name, 2008
          • Table 1.17: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.17: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.9 Cholesterol Reducers/Statins
          • Table 1.18: Sales by Type/Drug Name, 2008
          • Figure 1.18: Market Positions (Share) by Drug Name, 2008
          • Table 1.19: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.19: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.10 Diabetes Drugs
          • Table 1.20: Sales by Type/Drug Name, 2008
          • Figure 1.20: Market Positions (Share) by Drug Name, 2008
          • Table 1.21: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.21: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
          • Table 1.22: Sales by type/Drug Name, 2008
          • Figure 1.22: Market Positions (Share) by Drug Name, 2008
          • Table 1.23: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.23: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.12 Hormonal Drugs
          • Table 1.24: Sales by Type/Drug Name, 2008
          • Figure 1.24: Market Positions (Share) by Drug Name, 2008
          • Table 1.25: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.25: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.13 Osteoporosis and Hypercalcemia Drugs
          • Table 1.26: Sales by Type/Drug Name, 2008
          • Figure 1.26: Market Positions (Share) by Drug Name, 2008
          • Table 1.27: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.27: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.14 Sleeping Agents
          • Table 1.28: Sales by Type/Drug Name, 2008
          • Figure 1.28: Market Positions (Shape) by Drug Name, 2008
          • Table 1.29: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.29: Sales Growth by Brand, 2008 - 2013
        • 1.1.3.2.15 Other Drugs
          • Table 1.30: Sales by Type/Drug Name, 2008
          • Figure 1.30: Market Positions (Share) by Drug Name, 2008
          • Table 1.31: Sales by Brand in $MM, 2008 - 2013
          • Figure 1.31: Sales Growth by Brand, 2008 - 2013
  • 1.2 Growth Trends for Global Generics and Biogenerics Drug Market, 2008 - 2013
    • Table 1.32: R&D for Global Biogeneric Drugs by Compnay/R&D Activities/Expected Market Entry
  • 1.3 Summary of Global Generics and Biogenerics Drug Market, 2008 - 2013
    • 1.3.1 Global Sales of Generic and Biogeneric Drugs, 2008 - 2013
      • Table 1.33: Global Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
    • 1.3.2 Global Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
      • Table 1.34: Global Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
    • 1.3.3 Issues, Sales Drivers and Restraints

2. U.S. Market: Generic and Biogeneric Drugs

  • 2.1 The Generic and Biogeneric Drug Landscape in the U.S.
    • 2.1.1 U.S Healthcare Spending and Patient Demographics
    • 2.1.2 U.S Prescription Volume for Generic and Biogeneric Drugs
    • 2.1.3 U.S Sales of Generic and Biogeneric Drugs
      • 2.1.3.1 U.S. Sales of Generic and Biogeneric Drugs by Company
        • Table 2.1: U.S. Sales of Generic and Biogeneric Drugs by Company, 2008
        • Figure 2.1: U.S. Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
      • 2.1.3.2 U.S. Sales of Generic and Biogeneric Drugs by Category Common Research Item
        • Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
        • Figure: Market Positions (Shape) by Drug Name, 2008
        • Table: Sales by Brand in $MM, 2008 - 2013
        • Figure: Sales by Brand, 2008 - 2013
        • 2.1.3.2.1 Allergy Drugs
        • 2.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
        • 2.1.3.2.3 Anesthetics
        • 2.1.3.2.4 Anti-Convulsants
        • 2.1.3.2.5 Anti-Infectives
        • 2.1.3.2.6 Cancer Drugs
        • 2.1.3.2.7 Cardiovascular Drugs
        • 2.1.3.2.8 CNS and Psychotherapeutic Drugs
        • 2.1.3.2.9 Cholesterol Reducers/Statins
        • 2.1.3.2.10 Diabetes Drugs
        • 2.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
        • 2.1.3.2.12 Hormonal Drugs
        • 2.1.4.3.13 Osteoporosis and Hypercalcemia Drugs
        • 2.1.4.3.14 Sleeping Agents
        • 2.1.4.3.15 Other Drugs
  • 2.2 Growth Trends for the U.S. Generics and Biogenerics Drug Market, 2008 - 2013
    • Table 2.31: R&D for U.S. Biogeneric Drugs by Compnay/R&D Activities/Expected U.S. Market Entry
  • 2.3 Summary of U.S. Generics and Biogenerics Drug Market, 2008 - 2013
    • 2.3.1 U.S. Sales of Generic and Biogeneric Drugs, 2008 - 2013
      • Table 2.32: U.S. Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
    • 2.3.2 U.S. Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
      • Table 2.33: U.S. Prescription Volume for Generic and Biogeneric Drugs by Segement in Millions, 2008 - 2013
    • 2.3.3 Issues, Sales Drivers and Restraints

3. European Market: Generic and Biogeneric Drugs

  • 3.1 The Generic and Biogeneric Drug Landscape in the EU
    • 3.1.1 EU Healthcare Spending and Patient Demographics
    • 3.1.2 EU Prescription Volume for Generic and Biogeneric Drugs
    • 3.1.3 EU Sales of Generic and Biogeneric Drugs
      • 3.1.3.1 EU Sales of Generic and Biogeneric Drugs by Company
        • Table 3.1: EU Sales of Generic and Biogeneric Drugs by Company, 2008
        • Figure 3.1: EU Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
      • 3.1.3.2 EU Sales of Generic and Biogeneric Drugs by Category Common Research Item
        • Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
        • Figure: Market Positions (Shape) by Drug Name, 2008
        • Table: Sales by Brand in $MM, 2008 - 2013
        • Figure: Sales by Brand, 2008 - 2013
        • 3.1.3.2.1 Allergy Drugs
        • 3.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
        • 3.1.3.2.3 Anesthetics
        • 3.1.3.2.4 Anti-Convulsants
        • 3.1.3.2.5 Anti-Infectives
        • 3.1.3.2.6 Cancer Drugs
        • 3.1.3.2.7 Cardiovascular Drugs
        • 3.1.3.2.8 CNS and Psychotherapeutic Drugs
        • 3.1.3.2.9 Cholesterol Reducers/Statins
        • 3.1.3.2.10 Diabetes Drugs
        • 3.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
        • 3.1.3.2.12 Hormonal Drugs
        • 3.1.3.2.13 Osteoporosis and Hypercalcemia Drugs
        • 3.1.3.2.14 Sleeping Agents
        • 3.1.3.2.15 Other Drugs
  • 3.2 Growth Trends for the EU Generics and Biogenerics Drug Market, 2008 -2013
    • Table 3.32: R&D for EU Biogeneric Drugs by Company/R&D Activities/Expected Market Entry
  • 3.3 Summary of EU Generics and Biogenerics Drug Market, 2008 - 2013
    • 3.3.1 EU Sales of Generic and Biogeneric Drugs, 2008 - 2013
      • Table 3.33: EU Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
    • 3.3.2 EU Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
      • Table 3.34: EU Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
    • 3.3.3 Issues, Sales Drivers and Restraints

4. Japanese Market: Generic and Biogeneric Drugs

  • 4.1 The Generic and Biogeneric Drug Landscape in Japan
    • 4.1.1 Japan Healthcare Spending and Patient Demographics
    • 4.1.2 Japan Prescription Volume for Generic and Biogeneric Drugs
    • 4.1.3 Japan Sales of Generic and Biogeneric Drugs
      • 4.1.3.1 Japan Sales of Generic and Biogeneric Drugs by Company
        • Table 4.1: Japan Sales of Generic and Biogeneric Drugs by Company, 2008
        • Figure 4.1: Japan Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
      • 4.1.3.2 Japan Sales of Generic and Biogeneric Drugs by Category Common Research Item
        • Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
        • Figure: Market Positions (Shape) by Drug Name, 2008
        • Table: Sales by Brand in $MM, 2008 - 2013
        • Figure: Sales by Brand, 2008 - 2013
        • 4.1.3.2.1 Allergy Drugs
        • 4.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
        • 4.1.3.2.3 Anti-Convulsants
        • 4.1.3.2.4 Anti-Infectives
        • 4.1.3.2.5 Cardiovascular Drugs
        • 4.1.3.2.6 CNS and Psychotherapeutic Drugs
        • 4.1.3.2.7 Cholesterol Reducers/Statins
        • 4.1.3.2.8 Diabetes Drugs
        • 4.1.3.2.9 Gastrointestinal Drugs/Proton Pump Inhibitors
        • 4.1.3.2.10 Hormonal Drugs
        • 4.1.3.2.11 Sleeping Agents
        • 4.1.3.2.12 Other Drugs
  • 4.2 Growth Trends for Japan Generics and Biogenerics Drug Market, 2008 - 2013
    • Table 4.25: R&D for Japanese Biogeneric Drugs by Company/R&D Activities/Expected Market Entry
  • 4.3 Summary of Japan Generics and Biogenerics Drug Market, 2008 - 2013
    • 4.3.1 Japan Sales of Generic and Biogeneric Drugs, 2008 - 2013
      • Table 4.26: Japan Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
    • 4.3.2 Japanese Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
      • Table 4.27: Japan Prescription Volume for Generic and Biogeneric Drugs in Millions by Segment, 2008 - 2013
    • 4.3.3 Issues, Sales Drivers and Restraints

5. Rest of World (ROW): Generic and Biogeneric Drugs

  • 5.1 The Generic and Biogeneric Drug Landscape in the ROW
    • 5.1.1 ROW Healthcare Spending and Patient Demographics
    • 5.1.2 ROW Prescription Volume for Generic and Biogeneric Drugs
    • 5.1.3 ROW Sales of Generic and Biogeneric Drugs
      • 5.1.3.1 ROW Sales of Generic and Biogeneric Drugs by Company
        • Table 5.1: ROW Sales of Generic and Biogeneric Drugs by Company, 2008
        • Figure 5.1: ROW Market Positions of Manufacturers of Generic and Biogeneric Drugs by Company, 2008
      • 5.1.3.2 ROW Sales of Generic and Biogeneric Drugs by Category Common Research Item
        • Table: Sales by Indication/Drug Name or Type/Drug Name, 2008
        • Figure: Market Positions (Shape) by Drug Name, 2008
        • Table: Sales by Brand in $MM, 2008 - 2013
        • Figure: Sales by Brand, 2008 - 2013
        • 5.1.3.2.1 Allergy Drugs
        • 5.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs
        • 5.1.3.2.3 Anesthetics
        • 5.1.3.2.4 Anti-Convulsants
        • 5.1.3.2.5 Anti-Infectives
        • 5.1.3.2.6 Cancer Drugs
        • 5.1.3.2.7 Cardiovascular Drugs
        • 5.1.3.2.8 CNS and Psychotherapeutic Drugs
        • 5.1.3.2.9 Cholesterol Reducers/Statins
        • 5.1.3.2.10 Diabetes Drugs
        • 5.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors
        • 5.1.3.2.12 Hormonal Drugs
        • 5.1.3.2.13 Osteoporosis and Hypercalcemia Drugs
        • 5.1.3.2.14 Sleeping Agents
        • 5.1.3.2.15 Other Drugs
  • 5.2 Growth Trends for the ROW Generics and Biogenerics Drug Market by Company/R&D Activities/Expected Market Entry, 2008 - 2013
    • Table 5.31: R&D for ROW Biogeneric Drugs
  • 5.3 Summary of ROW Generics and Biogenerics Drug Market, 2008 - 2013
    • 5.3.1 EU Sales of Generic and Biogeneric Drugs, 2008 - 2013
      • Table 5.32: ROW Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013
    • 5.3.2 ROW Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013
      • Table 5.33: ROW Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013
    • 5.3.3 Issues, Sales Drivers and Restraints

6. Activities of Generic and Biogeneric Drug Makers

  • Common Research Item
    • Profile
    • Contact
    • URL
    • Sales 2008
    • Generic and Biogeneric Drug Sales 2008
    • Generic Drug Categories
  • 6.1 ~ 6.37 (Total 37 Companies)

7. Appendix

  • 7.1 Selected Companies Mentioned in this Report
    • Table 7.1: Major Generic and Biogeneric Companies
Back to Top